Urs Schwitter

This inventor holds 21 USPTO granted patents and 9 published patent applications, plus 2 CIPO patents and 11 EPO patents, primarily in Pharmaceutical Formulations. Top assignees: Hoffmann-La Roche Inc., F. Hoffmann-La Roche Ag, Oryzon Genomics S.a.. Active years: 2007-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Urs Schwitter. Retrieved from https://idiyas.com/inventor/urs-schwitter

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 21 (Patent Applications = 9)

% Patents Active = 61.9

CIPO Patents = 2 (Patent Applications = 4)

EPO Patents = 11 (Patent Applications = 14)

Average Co-Inventor Count = 5.7

ph-index = 2

Forward Citations = 69(Granted Patents)

Location History:

Reinach BL, CH (2011 - 2019)
Reinach, CH (2007 - 2021)
Basel, CH (2017 - 2024)

Company Filing History:

19 out of 5,035

Hoffmann-La Roche Inc.

patents

1 out of 182

F. Hoffmann-La Roche Ag

where one patent can have more than one assignee

Years Active: 2007-2026

Loading Chart...

Areas of Expertise:

Pharmaceutical Formulations

Solid Forms

Synthesis Processes

TAAR1 Agonist

Crystalline Forms

Co-crystals

DPPIV Inhibitor

X-ray Diffraction

Active Compounds

Polymorphs

Multi-well Filtration

Substance Properties

21 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12692256 - Salts and crystalline forms of a TAAR1 agonist (2026-07-28),

2. 12459947 - Synthesis of trans-8-chloro-5-methyl-1 -[4-(pyridin-2-yloxy)-cyclohexyl]-5,6-dihydro-4H-2,3,5,10B-tetraaza-benzo[e]azulene and crystalline forms thereof (2025-11-04),

3. 12122789 - Forms of pyrido[1,2-a]pyrimidin-4-one derivatives, its formulation and its process of making (2024-10-22),

4. 12012421 - Solid forms of [(1S)-1-[(2S,4R,5R)-5-(5-amino-2-oxo-thiazolo[4,5-d]pyrimidin-3-yl)-4-hydroxy-tetrahydrofuran-2-yl]propyl] acetate (2024-06-18),

5. 12012420 - Solid forms of [(1S)-1-[(2S,4R,5R)-5-(5-amino-2-oxo-thiazolo[4,5-d]pyrimidin-3-yl)-4-hydroxy-tetrahydrofuran-2-yl]propyl] acetate (2024-06-18),

6. 11230559 - Solid forms of [(1 S)-1 -[(2S,4R,5R)-5-(5-amino-2-oxo-thiazolo[4,5-D]pyrimidin-3-yl)-4-hydroxy-tetrahydrofuran-2-Yl]proptl] acetate (2022-01-25),

7. 11040977 - Synthesis of trans-8-chloro-5-methyl-1-[4-(pyridin-2-yloxy)-cyclohexyl]-5,6-dihydro-4H-2,3,5,10B-tetraaza-benzo[e]azulene and crytalline forms thereof (2021-06-22),

8. 10919041 - Preparing and analyzing solid form properties of a substance (2021-02-16),

9. 10246460 - Synthesis of trans-8-chloro-5-methyl-1-[4-(pyridin-2-yloxy)-cyclohexyl]-5,6-dihydro-4H-2,3,5,10B-tetraaza-benzo[E]azulene and crytalline forms thereof (2019-04-02),

10. 10227298 - Solid forms of a pharmaceutically active compound (2019-03-12),

11. 10221125 - Solid forms (2019-03-05),

12. 9676793 - Co-crystals of 5-amino-2-oxothiazolo[4,5-d]pyrimidin-3(2H)-yl-5-hydroxymethyl tetrahydrofuran-3-yl acetate and methods for preparing and using the same (2017-06-13),

13. 9562009 - Process to manufacture N-[(3S)-1-[4-[(3-fluorophenyl)methoxy]phenyl]-5-oxo-pyrrolidin-3-yl]acetamide (2017-02-07),

14. 8975397 - Solid forms (2015-03-10),

15. 8865735 - Solid forms of a pharmaceutically active substance (2014-10-21),

Title: Urs Schwitter: Pharmaceutical Chemistry and Patent Innovation

Introduction

Urs Schwitter is an inventor based in Reinach, Switzerland. His patent work includes pharmaceutical compounds, crystalline forms, and processes for preparing potential therapeutic agents. He is associated with Hoffmann-La Roche Inc. and Oryzon Genomics S.A. His portfolio includes 21 patents.

Latest Patents

One of Schwitter’s recent patent topics concerns salts and crystalline forms of a TAAR1 agonist. The invention describes amorphous and crystalline forms of pharmaceutically acceptable salts of 5-ethyl-4-methyl-N-[4-[(2S)-morpholin-2-yl]phenyl]-1H-pyrazole-3-carboxamide. It also covers pharmaceutical compositions containing the agonist and methods of using it, alone or with other compounds, to treat diseases or conditions associated with TAAR1 activity.

Another patent concerns the synthesis of trans-8-chloro-5-methyl-1-[4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4H-2,3,5,10b-tetraaza-benzo[e]azulene and its crystalline forms. The invention describes manufacturing processes for substituted tetraaza-benzo[e]azulenes and compounds that can serve as intermediates in those processes.

Career Highlights

Schwitter’s listed company affiliations include Hoffmann-La Roche Inc. and Oryzon Genomics S.A. The patent subjects provided reflect work involving pharmaceutical chemistry, compound synthesis, and the development of solid forms relevant to drug preparation.

Collaborations

Schwitter’s named coworkers include Olaf Grassmann and Ralph Diodone. Their names are associated with his professional and patent-related collaborations.

Conclusion

Urs Schwitter’s patent portfolio highlights contributions to pharmaceutical research, including TAAR1 agonist forms and synthetic methods for complex compounds.

Profile summary based on public USPTO records.